The goal of this clinical trial is to evaluate the effectiveness and safety of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in peritoneal metastatic pancreatic cancer. The main question it aims to answer are:
(1) Does this combined approach increase 1-year survival rates? and (2) What is the safety profile of this treatment regimen?
Participants will:
undergo baseline imaging and surgical exploration to confirm peritoneal metastasis, receive two cycles of intraperitoneal cisplatin HIPEC (70mg/m²) postoperatively, followed by systemic AG chemotherapy (nab-paclitaxel plus gemcitabine), with treatment adjustments based on regular imaging assessments and multidisciplinary team (MDT) recommendations.
Obtain signed informed consent from the patient or their legal representative, with adherence to the study protocol and follow-up procedures;
Aged >=18 and <=80 years, regardless of gender;
No contraindications to surgery, with an ECOG performance status of 0-1;
Confirmed peritoneal metastasis by imaging or intraoperative detection, with rapid intraoperative histopathology indicating metastatic adenocarcinoma;
Presence of distant metastases to other organs (e.g., liver, bone, lung) with definitive evidence, except for ovarian metastases;
History of other systemic malignancies within the past five years;
Use of any non-anti-tumor investigational drugs within 4 weeks prior to treatment;
Accompanied by massive ascites (extending from pelvic to upper abdominal cavity);